Key Points: Bio Protocol raises $6.9M with Maelstrom lead. Massive institutional backing confirms DeSci potential. $BIO token maintains stability despite fundraising. Bio Protocol Raises $6.9M in Seed Round Bio Protocol raised $6.9 million in a seed funding round led by Arthur Hayes’ Maelstrom Fund with participation from major institutional investors, boosting its total raised to $17 million. The fundraising indicates strong confidence in decentralized science platforms and could accelerate Bio Protocol’s development, although immediate token price reactions remain stable. Bio Protocol, a decentralized science platform, successfully raised $6.9 million in a seed round led by Arthur Hayes’ Maelstrom Fund. Major contributions came from institutional investors like Mechanism Capital and Animoca Brands, reflecting significant interest in decentralized science. In this funding round, Arthur Hayes, ex-CEO of BitMEX, played a pivotal role as the lead investor through his Maelstrom Fund. The involvement of prominent funds such as Mechanism Capital and Animoca Brands underscores the substantial backing for the project. The influx of $6.9 million brought Bio Protocol’s total raised to approximately $17 million. Despite the funding news, $BIO token prices showed no direct volatility, maintaining a trading value of $0.1604 with a market cap of $310 million. Despite the fundraising, no immediate on-chain activity spikes were evident. High-profile investments suggest heightened trust in the DeSci market, yet financial impacts remain isolated to the $BIO token without broader implications on other crypto-assets. Historical data indicates that similar decentralized science initiatives resulted in modest price shifts. Bio Protocol’s continued growth depends on roadmap execution and user adoption rather than immediate market movements. The fundraising highlights strong confidence in decentralized science’s potential but provides limited immediate financial impact. Historical trends show minor liquidity changes in similar cases, directing attention to Bio Protocol’s capacity for innovation and technological development. “The involvement of major VC funds indicates a growing confidence in decentralized science’s future.” [Source: ChainCatcher] Disclaimer:The content on The CCPress is provided for informational purposes only and should not be considered financial or investment advice. Cryptocurrency investments carry inherent risks. Please consult a qualified financial advisor before making any investment decisions.
Cardano, Ripple Lead Crypto Regulation Talks
Cardano and Ripple join U.S. lawmakers for key bipartisan crypto regulation discussions, marking significant policy progress.